Correlation Between Eyepoint Pharmaceuticals and Cullinan Oncology

Can any of the company-specific risk be diversified away by investing in both Eyepoint Pharmaceuticals and Cullinan Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eyepoint Pharmaceuticals and Cullinan Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eyepoint Pharmaceuticals and Cullinan Oncology LLC, you can compare the effects of market volatilities on Eyepoint Pharmaceuticals and Cullinan Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eyepoint Pharmaceuticals with a short position of Cullinan Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eyepoint Pharmaceuticals and Cullinan Oncology.

Diversification Opportunities for Eyepoint Pharmaceuticals and Cullinan Oncology

0.76

Correlation Coefficient

Eyepoint Pharmaceuticals  Cullinan Oncology

Poor diversification

The 3 months correlation between Eyepoint and Cullinan is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Eyepoint Pharmaceuticals and Cullinan Oncology LLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cullinan Oncology LLC and Eyepoint Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eyepoint Pharmaceuticals are associated (or correlated) with Cullinan Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cullinan Oncology LLC has no effect on the direction of Eyepoint Pharmaceuticals i.e., Eyepoint Pharmaceuticals and Cullinan Oncology go up and down completely randomly.

Pair Corralation between Eyepoint Pharmaceuticals and Cullinan Oncology

Given the investment horizon of 90 days Eyepoint Pharmaceuticals is expected to generate 1.57 times more return on investment than Cullinan Oncology. However, Eyepoint Pharmaceuticals is 1.57 times more volatile than Cullinan Oncology LLC. It trades about -0.07 of its potential returns per unit of risk. Cullinan Oncology LLC is currently generating about -0.2 per unit of risk. If you would invest  837.00  in Eyepoint Pharmaceuticals on December 3, 2024 and sell it today you would lose (210.00) from holding Eyepoint Pharmaceuticals or give up 25.09% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Eyepoint Pharmaceuticals  vs.  Cullinan Oncology LLC

Eyepoint Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Eyepoint Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Cullinan Oncology LLC

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cullinan Oncology LLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Eyepoint Pharmaceuticals and Cullinan Oncology

The main advantage of trading using opposite Eyepoint Pharmaceuticals and Cullinan Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eyepoint Pharmaceuticals position performs unexpectedly, Cullinan Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cullinan Oncology will offset losses from the drop in Cullinan Oncology's long position.

The idea behind Eyepoint Pharmaceuticals and Cullinan Oncology LLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.